Janus Henderson Group PLC lowered its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 97.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,261 shares of the biotechnology company's stock after selling 3,838,158 shares during the period. Janus Henderson Group PLC's holdings in ADMA Biologics were worth $884,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. Summit Securities Group LLC bought a new position in ADMA Biologics in the 4th quarter worth approximately $29,000. Optima Capital LLC bought a new stake in ADMA Biologics during the 4th quarter valued at $36,000. iSAM Funds UK Ltd bought a new stake in ADMA Biologics during the 3rd quarter valued at $34,000. Morse Asset Management Inc purchased a new stake in shares of ADMA Biologics during the fourth quarter worth $44,000. Finally, Nkcfo LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter worth $47,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.
More ADMA Biologics News
Here are the key news stories impacting ADMA Biologics this week:
- Neutral Sentiment: The August 10, 2026 deadline allows investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, to apply to become lead plaintiff. The notices state that eligible investors may pursue compensation through a contingency-fee arrangement, but the announcements do not establish that ADMA violated securities laws. Rosen Law Firm deadline notice
- Negative Sentiment: Hagens Berman said the lawsuit concerns alleged misrepresentations about ADMA’s financial condition, revenue recognition, inventory distribution and business practices. The allegations could increase legal costs, create potential liability and undermine investor confidence if they proceed. Hagens Berman class-action notice
- Negative Sentiment: Rosen, Faruqi & Faruqi, DJS Law Group and Schall, Brown & Schwartz separately promoted the pending securities action and encouraged affected shareholders to contact them. The unusually large number of substantially similar notices may amplify short-term headline pressure on ADMA, although they largely repeat the same underlying litigation information. Faruqi & Faruqi class-action deadline DJS Law Group lawsuit notice
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on ADMA. Raymond James Financial started coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 price target for the company. Mizuho dropped their price objective on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Canaccord Genuity Group cut their target price on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Zacks Research lowered ADMA Biologics from a "hold" rating to a "strong sell" rating in a report on Tuesday, August 4th. Finally, Wall Street Zen cut ADMA Biologics from a "buy" rating to a "hold" rating in a research report on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $18.67.
Get Our Latest Stock Report on ADMA
ADMA Biologics Stock Down 1.5%
ADMA stock opened at $9.75 on Tuesday. The company's 50 day moving average is $8.67 and its 200 day moving average is $11.21. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 13.93 and a beta of 0.74. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. During the same period in the previous year, the business posted $0.14 earnings per share. ADMA Biologics's revenue for the quarter was up 2.0% on a year-over-year basis. Sell-side analysts predict that ADMA Biologics Inc will post 0.76 EPS for the current fiscal year.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
